Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Hearth and Stroke grant 1998 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Heart and Stroke Foundation of Canada | OTHER |
Compare heparin/warfarin to ASA for thromboembolic prophylaxis in the first two years following Fontan procedures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Warfarin vs ASA | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Warfarin vs ASA in prevention of thrombosis 2 yrs after Fontan |
| Measure | Description | Time Frame |
|---|---|---|
| Identify subpopulation of Fontan pts at high risk for TEs | ||
| Determine high risk period for TEs in first 2 yrs post Fontan |
Not provided
Inclusion Criteria:
1. Patient is scheduled to have a Fontan or modified Fontan procedure
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paul Monagle, MD | Royal Children's Hospital, Parkville, Victoria, Australia | Study Chair |
| Brian McCrindle, MD | The Hospital for Sick Children | Principal Investigator |
| Robin Roberts, MD | McMaster University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Children's Hospital | Parkville | Victoria | 3052 | Australia | ||
| Alberta Children's Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23246393 | Derived | McCrindle BW, Manlhiot C, Cochrane A, Roberts R, Hughes M, Szechtman B, Weintraub R, Andrew M, Monagle P; Fontan Anticoagulation Study Group. Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol. 2013 Jan 22;61(3):346-53. doi: 10.1016/j.jacc.2012.08.1023. Epub 2012 Dec 12. | |
| 21798429 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D013927 | Thrombosis |
| D013923 | Thromboembolism |
| ID | Term |
|---|---|
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Calgary |
| Alberta |
| T2T 5C7 |
| Canada |
| University of Alberta HSC | Edmonton | Alberta | T6G 2R7 | Canada |
| BC Children's Hospital | Vancouver | British Columbia | V6H 3V4 | Canada |
| IWK Health Centre | Halifax | Nova Scotia | B3J 3G9 | Canada |
| Sick Children's Hospital | Toronto | Ontario | Canada |
| Hopital Ste-Justine | Montreal | Quebec | H3T 1C5 | Canada |
| Derived |
| Monagle P, Cochrane A, Roberts R, Manlhiot C, Weintraub R, Szechtman B, Hughes M, Andrew M, McCrindle BW; Fontan Anticoagulation Study Group. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol. 2011 Aug 2;58(6):645-51. doi: 10.1016/j.jacc.2011.01.061. |